FDA Warning Letter: Critical Quality Issues Only Addressed Because of FDA Inspection?

The U.S. Food and Drug Administration (FDA) recently issued a Warning Letter dated 20 September 2024, to a Massachusetts-based company, referencing an inspection conducted in the first quarter of 2023.

The letter highlights several serious compliance issues. Notably, many of these problems, such as product crystallization and potential lead contamination, seem to have been addressed only because the FDA initiated an inspection. The letter underscores that these critical issues were not properly investigated until after the inspection began, raising concerns about the company's internal oversight and commitment to maintaining quality standards prior to regulatory inspection.

Complaints

The company’s Quality Unit (QU) received over 80 complaints of crystallization in two injection batches between December 2022 and February 2023. However, this issue was not investigated until the FDA inspection was initiated, prompting a Field Alert Report and batch recalls before the inspection ended.

Additionally, the Warning Letter details a failure to fully investigate consumer complaints about potential lead contamination in two batches, focusing only on one batch while leaving another unexamined. No testing for lead was conducted, raising concerns about ineffective corrective actions and unresolved root causes.

Stability Testing

The company also failed to establish a robust stability testing program. Since 2019, unknown impurities were detected in some batches, yet no root cause was determined. Despite consistent out-of-specification (OOS) results, the company did not take effective corrective actions, risking the safety and efficacy of their drug products.

Unapproved Drug Products

The letter further highlights that several of the company's products, including the FIRST® Unit-of-Use Kits (Lansoprazole, Pantoprazole, Metronidazole, and Mouthwash BLM), were being marketed without FDA approval. These products, classified as “new drugs” under the FD&C Act, require FDA approval to ensure safety and effectiveness before they can be distributed. The absence of such approval makes the marketing of these products illegal under U.S. law.

Conclusion

The company must take prompt action to correct the identified violations, improve their quality systems, and ensure compliance with FDA regulations to avoid further legal consequences. The FDA has indicated that failure to comply could result in withholding of approvals for new drug applications and other enforcement measures.

For further details, refer to the full FDA Warning Letter to Azurity Pharmaceuticals, Inc. on the FDA's website.